Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$65.68 USD

65.68
3,456,884

-1.42 (-2.12%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (59 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

3 Reasons Growth Investors Will Love DexCom (DXCM)

DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.

What Makes DexCom (DXCM) a New Buy Stock

DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Ensign Group (ENSG) Q3 Earnings Beat on Occupancy, Stock Up 2.4%

Ensign Group's (ENSG) third-quarter results benefit on solid segmental contribution and occupancy strength. Management currently expects adjusted EPS to be within $4.73-$4.79 for 2023.

DexCom (DXCM) Beats on Q3 Earnings, Raises Sales Outlook

DexCom's (DXCM) third-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

DexCom (DXCM) Reports Q3 Earnings: What Key Metrics Have to Say

The headline numbers for DexCom (DXCM) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates

DexCom (DXCM) delivered earnings and revenue surprises of 47.06% and 4.02%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

MedTech Stocks to Watch for Earnings on Oct 26: WST, DXCM & More

MedTech companies' Q3 results are likely to reflect strength in customer demand. Let's see how WST, DXCM, MMSI and ITGR are placed ahead of their earnings releases.

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

DexCom (DXCM) to Report Q3 Earnings: Is a Beat in Store?

DexCom's (DXCM) third-quarter 2023 results are likely to reflect rising volumes across all channels.

Will Patient Volumes Aid Community Health's (CYH) Q3 Earnings?

Community Health's (CYH) third-quarter results are likely to benefit from improved payer mix and growing surgery volumes, partly offset by a decline in patient days.

What's in Store for West Pharmaceutical (WST) in Q3 Earnings?

West Pharmaceutical's (WST) third-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.

DexCom (DXCM) Earnings Expected to Grow: Should You Buy?

DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Indrajit Bandyopadhyay headshot

4 Medical Product Stocks Set to Outpace Q3 Earnings Estimates

Medical Product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EW, PODD, DXCM and IQV are poised ahead of their earnings release.

Can DexCom (DXCM) Keep the Earnings Surprise Streak Alive?

DexCom (DXCM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Market Dipped But DexCom (DXCM) Gained Today

The latest trading day saw DexCom (DXCM) settling at $80.49, representing a +1.95% change from its previous close.

DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know

DexCom (DXCM) closed the most recent trading day at $83.09, moving -0.16% from the previous trading session.

Here's Why DexCom (DXCM) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

DexCom (DXCM) to Launch Latest CGM System G7 in Canada

DexCom's (DXCM) G7 CGM System (launched in Canada) is expected to combine simplicity and power, thereby providing a better way to manage diabetes.

DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, DexCom (DXCM) closed at $94.55, marking a +1.34% move from the previous day.

Benjamin Rains headshot

Buy this Tech Stock on the Dip in October for 50% Upside?

DXCM stock is currently down over 40% from its 2021 highs and trading 51% below its average Zacks price target even though it stands out in the connected health world that's likely to become standard medical practice.

Dynatronics Corporation (DYNT) Reports Q4 Loss, Tops Revenue Estimates

Dynatronics Corporation (DYNT) delivered earnings and revenue surprises of -85.29% and 5.02%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

DexCom (DXCM) Partners With RxFood for Automated Dietary Monitoring

DexCom's (DXCM) CGM systems will make dietary assessment through AI-enabled RxFood app, which automatically interprets food images for calorie count in Canada.

Should Vanguard Mid-Cap Growth ETF (VOT) Be on Your Investing Radar?

Style Box ETF report for VOT

DexCom (DXCM) Dips More Than Broader Markets: What You Should Know

DexCom (DXCM) closed at $94.16 in the latest trading session, marking a -1.19% move from the prior day.

Should Vanguard Mid-Cap ETF (VO) Be on Your Investing Radar?

Style Box ETF report for VO